Overview

Spiriva (Tiotropium Bromide) Assessment of FEV1 - (SAFE-Portugal).

Status:
Completed
Trial end date:
2004-04-01
Target enrollment:
Participant gender:
Summary
Evaluate whether the effect of inhaled tiotropium bromide on the change in trough forced expiratory volume (FEV1), compared to placebo in patients with chronic obstructive pulmonary disease (COPD), is affected by smoking status.
Phase:
Phase 4
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Bromides
Tiotropium Bromide